Jennifer Tousignant
About Jennifer Tousignant
Jennifer Tousignant serves as the Chief Legal Officer at Viridian Therapeutics, Inc. and has extensive experience in the biotech and pharmaceutical sectors, holding various senior legal positions across multiple companies.
Work at Sana Biotechnology
Jennifer Tousignant currently serves as Senior Vice President, Legal at Sana Biotechnology, Inc. since 2022. In this role, she oversees legal matters and provides strategic legal guidance across various departments within the organization. Her responsibilities include managing legal transactional teams and ensuring compliance with regulatory requirements. Prior to her current position, she worked at Viridian Therapeutics, Inc. as Chief Legal Officer starting in 2024.
Education and Expertise
Jennifer Tousignant holds a Juris Doctor degree, magna cum laude, from Suffolk University Law School, which she completed from 2003 to 2007. She also studied at Harvard Business School, earning a Certificate in Organizational Leadership from 2014 to 2015. Additionally, she obtained a Bachelor's Degree in Chemistry from the University of Virginia from 1989 to 1993. Her educational background supports her deep understanding of the biotech and pharmaceutical sectors.
Background
Jennifer Tousignant began her career in the biotech industry at Genzyme, where she worked in various roles from 1993 to 2002 and later as Senior Patent Counsel from 2003 to 2016. She transitioned to TESARO, Inc. as Vice President, Chief Intellectual Property Counsel from 2016 to 2019. After her time at TESARO, she held positions at Xilio Therapeutics, Inc. and has extensive experience in managing legal teams and providing counsel in the biotech and pharma space.
Achievements
Throughout her career, Jennifer Tousignant has developed significant expertise in managing legal transactional and diligence teams for public financings, mergers and acquisitions, and asset purchase agreements. She has been involved in litigation settlements, including contract litigation and post-grant review proceedings. Her experience also includes drafting and reviewing SEC filings, such as 10K, 10Q, and 8K reports, and developing commercial global intellectual property strategies for drug launches.